StockNews.com Initiates Coverage on Affimed (NASDAQ:AFMD)

Analysts at StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the company. Leerink Partnrs lowered Affimed from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. HC Wainwright lowered Affimed from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $0.10 price target (down from $11.00) on shares of Affimed in a research note on Tuesday, May 13th. Leerink Partners reissued a “market perform” rating and issued a $0.39 price target (down previously from $5.00) on shares of Affimed in a research note on Tuesday, May 13th. Finally, Cantor Fitzgerald downgraded Affimed from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $7.90.

Affimed Stock Performance

Shares of AFMD opened at $0.18 on Monday. The business’s 50-day moving average is $0.70 and its 200-day moving average is $1.36. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a fifty-two week low of $0.07 and a fifty-two week high of $8.95.

Institutional Investors Weigh In On Affimed

A hedge fund recently raised its stake in Affimed stock. Intellectus Partners LLC lifted its position in Affimed (NASDAQ:AFMD) by 34.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 126,414 shares of the biopharmaceutical company’s stock after buying an additional 32,053 shares during the quarter. Intellectus Partners LLC owned about 0.79% of Affimed worth $150,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.